The initial clinical trial on ‘PNEUMOSTEM^®’ which is the stem cell lung disease medicine under development by MEDIPOST in U.S., was successfully administrated to a subject patient as the 1st and 2nd clinical trial.

MEDIPOST announced that ‘PNEUMOSTEM^®’ was initially administered to a 6 days’ old baby with low weight of 700 g as the clinical trial, on March 18 at Rush University Hospital in Chicago.

MEDIPOST will verify the safety and efficacy of ‘PNEUMOSTEM^®’ through clinical trials on 12 patients for 2 years from now on.

This clinical trial was registered at the clinicaltrials.gov, which is the registration site for official clinical trials in U.S.